Literature DB >> 22895508

Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein.

S Bobadilla1, N Sunseri, N R Landau.   

Abstract

Lentiviral vectors are widely used for the stable expression of genes and small hairpin RNA (shRNA)-mediated knockdown and are currently under development for clinical use in gene therapy. Pseudotyping of the vectors with VSV-G allows them to infect a wide range of cell types. However, myeloid cells, such as dendritic cells and macrophages, are relatively refractory to lentiviral vector transduction as a result of the myeloid-specific restriction factor, SAMHD1. SIVmac/HIV-2 and related viruses relieve the SAMHD1-mediated restriction by encoding Vpx, a virion-packaged accessory protein that induces the degradation of SAMHD1 upon infection. HIV-1 does not encode Vpx and cannot package the protein. We report the development of an HIV-1-based lentiviral vector in which the Vpx packaging motif has been placed in the p6 region of the Gag/Pol expression vector that is used to generate the lentiviral vector virions. The virions package Vpx in high copy number and infect myeloid cells with a two-log increase in titer. Transduction of dendritic cells with an shRNA against transportin-3 resulted in >90% knockdown of the encoding mRNA. The system can be applied to any HIV-based lentiviral vector and is useful for laboratory and clinical applications where the efficient transduction of myeloid cells is required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895508      PMCID: PMC4105013          DOI: 10.1038/gt.2012.61

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  36 in total

Review 1.  Lentiviruses as gene transfer agents for delivery to non-dividing cells.

Authors:  L Naldini
Journal:  Curr Opin Biotechnol       Date:  1998-10       Impact factor: 9.740

2.  Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.

Authors:  Redas Trepiakas; Annika Berntsen; Sine Reker Hadrup; Jon Bjørn; Poul F Geertsen; Per Thor Straten; Mads H Andersen; Anders E Pedersen; Amir Soleimani; Torben Lorentzen; Julia S Johansen; Inge Marie Svane
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

3.  [Gene therapy of x-linked adrenoleukodystrophy using hematopoietic stem cells and a lentiviral vector].

Authors:  Nathalie Cartier; Salima Hacein-Bey-Abina; Christof Von Kalle; Pierre Bougnères; Alain Fischer; Marina Cavazzana-Calvo; Patrick Aubourg
Journal:  Bull Acad Natl Med       Date:  2010-02       Impact factor: 0.144

4.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

5.  The cargo-binding domain of transportin 3 is required for lentivirus nuclear import.

Authors:  Eric C Logue; Kayleigh T Taylor; Peter H Goff; Nathaniel R Landau
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 6.  Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.

Authors:  Peter Manilla; Tessio Rebello; Cathleen Afable; Xiaobin Lu; Vladimir Slepushkin; Laurent M Humeau; Kathy Schonely; Yajin Ni; Gwendolyn K Binder; Bruce L Levine; Rob-Roy MacGregor; Carl H June; Boro Dropulic
Journal:  Hum Gene Ther       Date:  2005-01       Impact factor: 5.695

7.  HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Authors:  Anupama Sharma; Ursula Koldovsky; Shuwen Xu; Rosemarie Mick; Robert Roses; Elizabeth Fitzpatrick; Susan Weinstein; Harvey Nisenbaum; Bruce L Levine; Kevin Fox; Paul Zhang; Gary Koski; Brian J Czerniecki
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

8.  Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx.

Authors:  Thomas Gramberg; Nicole Sunseri; Nathaniel R Landau
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

9.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.

Authors:  Kasia Hrecka; Caili Hao; Magda Gierszewska; Selene K Swanson; Malgorzata Kesik-Brodacka; Smita Srivastava; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells.

Authors:  Caroline Goujon; Lise Rivière; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  Retrovirology       Date:  2007-01-09       Impact factor: 4.602

View more
  35 in total

1.  Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells.

Authors:  Joseph A Hollenbaugh; Susan M Schader; Raymond F Schinazi; Baek Kim
Journal:  Virology       Date:  2015-08-29       Impact factor: 3.616

2.  Macrophage-specific overexpression of interleukin-5 attenuates atherosclerosis in LDL receptor-deficient mice.

Authors:  W Zhao; T Lei; H Li; D Sun; X Mo; Z Wang; K Zhang; H Ou
Journal:  Gene Ther       Date:  2015-04-14       Impact factor: 5.250

3.  A combination HIV reporter virus system for measuring post-entry event efficiency and viral outcome in primary CD4+ T cell subsets.

Authors:  Carisa A Tilton; Caroline O Tabler; Mark B Lucera; Samantha L Marek; Aiman A Haqqani; John C Tilton
Journal:  J Virol Methods       Date:  2013-09-08       Impact factor: 2.014

4.  Vpr Targets TET2 for Degradation by CRL4VprBP E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1 Replication.

Authors:  Lei Lv; Qi Wang; Yanping Xu; Li-Chung Tsao; Tadashi Nakagawa; Haitao Guo; Lishan Su; Yue Xiong
Journal:  Mol Cell       Date:  2018-06-07       Impact factor: 17.970

5.  Toll-like receptor agonist R848 blocks Zika virus replication by inducing the antiviral protein viperin.

Authors:  Bénédicte Vanwalscappel; Takuya Tada; Nathaniel R Landau
Journal:  Virology       Date:  2018-07-20       Impact factor: 3.616

6.  Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection.

Authors:  Thomas D Norton; Takuya Tada; Rebecca Leibowitz; Verena van der Heide; Dirk Homann; Nathaniel R Landau
Journal:  Mol Ther       Date:  2020-05-20       Impact factor: 11.454

7.  A Highly Active Isoform of Lentivirus Restriction Factor SAMHD1 in Mouse.

Authors:  Nicolin Bloch; Sabine Gläsker; Poojitha Sitaram; Henning Hofmann; Caitlin N Shepard; Megan L Schultz; Baek Kim; Nathaniel R Landau
Journal:  J Biol Chem       Date:  2016-12-05       Impact factor: 5.157

Review 8.  Intrinsic host restrictions to HIV-1 and mechanisms of viral escape.

Authors:  Viviana Simon; Nicolin Bloch; Nathaniel R Landau
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

9.  Degradation of SAMHD1 by Vpx Is Independent of Uncoating.

Authors:  Paula Jáuregui; Eric C Logue; Megan L Schultz; Stephanie Fung; Nathaniel R Landau
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

10.  HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx.

Authors:  Nicolin Bloch; Meagan O'Brien; Thomas D Norton; Sylvie B Polsky; Nina Bhardwaj; Nathaniel R Landau
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09-04       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.